


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Cancel claims 27, 28 and 30-32 without prejudice.

1. (currently amended) A compound of formula (I):



wherein

$R^1$  and  $R^2$  are each independently selected from the group consisting of

- H,  $C_{1-7}$ alkyl,  $C_{2-7}$ alkenyl,  $C_{2-7}$ alkynyl,  $C_{3-7}$ cycloalkyl,  $C_{3-7}$ cycloalkenyl, benzo-fused  $C_{4-7}$ cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction,  $C_{3-7}$ cycloalkyl  $C_{1-7}$ alkyl,
  - naphthyl- $(CR^s_2)$ -, benzoyl  $C_{0-3}$ alkyl- $(CR^s_2)$ -, ~~phenyl-, said phenyl optionally~~ fused at two adjacent carbon atoms to  $R^f$ , phenyl- $(CR^s_2)$ -, said phenyl optionally fused at two adjacent carbon atoms to  $R^f$ ,
- $R^f$  is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,
- $Ar^6-(CR^s_2)$ -, where  $Ar^6$  is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused,
  - $Ar^5-(CR^s_2)$ -, where  $Ar^5$  is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting

- of O, S, >NH or >NC<sub>1-4</sub>alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzofused,
- c) Ar<sup>6-6</sup>-(CR<sup>s</sup><sub>2</sub>)-, where Ar<sup>6-6</sup> is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,
- f) Ar<sup>6-5</sup>-(CR<sup>s</sup><sub>2</sub>)-, where Ar<sup>6-5</sup> is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl and having 0 or 1 additional heteroatom member which is -N=,
- g) C<sub>1-4</sub>alkylO- and HSC<sub>1-4</sub>alkyl,

where R<sup>1</sup> and R<sup>2</sup> are not simultaneously H and, except in positions where R<sup>s</sup> is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R<sup>q</sup>,

R<sup>q</sup> is independently selected from the group consisting of C<sub>1-4</sub>alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl, diC<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl, HO-C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylO-C<sub>1-4</sub>alkyl, HS-C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylS-C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy and C<sub>1-4</sub>alkylS-,

R<sup>s</sup> is independently selected from the group consisting of hydrogen, C<sub>1-4</sub>alkyl, trifluoromethyl, aminoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl, diC<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl, HO-C<sub>1-4</sub>alkyl, HS-C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylS-C<sub>1-4</sub>alkyl and phenyl;

or, alternatively,

R<sup>1</sup> and R<sup>2</sup> may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

- i) 10-Oxa-4-aza-tricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl, optionally mono- or di-substituted with R<sup>p</sup>,

R<sup>p</sup> is independently selected from the group consisting of hydroxy, C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,


- ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl,

- optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R<sup>P</sup>,
- iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R<sup>P</sup>,
- iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R<sup>P</sup>;
- v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R<sup>P</sup>;
- R<sup>a</sup> is, independently, selected from the group consisting of -C<sub>1-6</sub>alkyl, -C<sub>2-6</sub>alkenyl, -C<sub>3-6</sub>cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC<sub>1-6</sub>alkyl, -OC<sub>3-6</sub>cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC<sub>1-6</sub>alkyl, -SC<sub>3-6</sub>cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO<sub>2</sub>, -N(R<sup>y</sup>)R<sup>z</sup> (wherein R<sup>y</sup> and R<sup>z</sup> are independently selected from H, C<sub>1-4</sub>alkyl or C<sub>1-6</sub>cycloalkylC<sub>1-4</sub>alkyl), -(C=O)C<sub>1-4</sub>alkyl, -SCF<sub>3</sub>, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, and -COOC<sub>1-4</sub>alkyl, or, alternatively, two adjacent R<sup>a</sup>, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;
- R<sup>b</sup> is, independently, selected from the group consisting of -C<sub>1-4</sub>alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof,

with the proviso that the compound of formula I cannot include compounds in which:

- A) one of  $R^1$  and  $R^2$  is phenyl substituted with 1, 2, or 3 of halo, and
- B) a compound of the formula:



2. (currently amended) The compound of claim 1 wherein  $R^1$  and  $R^2$  are, independently, selected from the group consisting of hydrogen,

a)  $C_{1-7}$ alkyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl, cyclobutyl $C_{1-4}$ alkyl, cyclopentyl $C_{1-4}$ alkyl, cyclohexyl $C_{1-4}$ alkyl, cycloheptyl $C_{1-4}$ alkyl,

b) phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-yl, optionally 5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-yl, optionally 5,6,7 or 8 oxo substituted, benzyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-ylmethyl, optionally 5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-ylmethyl, optionally 5,6,7 or 8 oxo substituted, 1-phenyleth-1-yl, benzhydryl, naphthylmethyl, benzoylmethyl, 1-benzoyleth-1-yl,

c) pyridylmethyl, pyrazinylmethyl, pyrimidinylmethyl, pyridazinylmethyl, quinolin-2,3 or 4-ylmethyl, isoquinolin-1,3 or 4-ylmethyl, quinazolin-2 or 4-ylmethyl, quinoxalin-2 or 3-ylmethyl,

d) furanylmethyl, thiophenylmethyl, 1-(H or  $C_{1-4}$ alkyl)pyrrolylmethyl, oxazolylmethyl, thiazolylmethyl, pyrazolylmethyl, imidazolylmethyl, isoxazolylmethyl,

isothiazolylmethyl, benzofuran-2 or 3-ylmethyl, benzothiophen-2 or 3-ylmethyl, 1-(H or C<sub>1-4</sub>alkyl)-1H-indol-2 or 3-ylmethyl, 1-(H or C<sub>1-4</sub>alkyl)-1H-benzimidazol-2-ylmethyl, benzooxazol-2-ylmethyl, benzothiazol-2-ylmethyl,

e) quinolin-5,6,7 or 8-ylmethyl, isoquinolin-5,6,7 or 8-ylmethyl, quinazolin-5,6,7 or 8-ylmethyl, quinoxalin-5,6,7 or 8-ylmethyl,

f) benzofuran-4,5,6 or 7-ylmethyl, benzothiophen-4,5,6 or 7-ylmethyl, 1-(H or C<sub>1-4</sub>alkyl)-1H-indol-4,5,6 or 7-ylmethyl, 1-(H or C<sub>1-4</sub>alkyl)-1H-benzimidazol-4,5,6 or 7-ylmethyl, benzooxazol-4,5,6 or 7-ylmethyl, benzothiazol-4,5,6 or 7-ylmethyl,

g) C<sub>1-4</sub>alkylO- and HSC<sub>1-4</sub>alkyl,

where each of a) to g) is substituted with 0, 1, 2, or 3 of R<sup>q</sup>.


3. (currently amended) The compound of claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are, independently, selected from the group consisting of hydrogen, methyl, ethyl, butyl, hexyl, ~~phenyl~~, 6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl, optionally 5,6,7,8 or 9 oxo substituted, benzyl, 1-phenyleth-1-yl, furanylmethyl, benzoylethyl, 1-benzoyleth-1-yl, methylO-, cyclohexyl, cyclohexylmethyl, pyridylethyl, naphthylmethyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, benzhydryl, where each member is substituted with 0, 1, 2, or 3 of R<sup>q</sup>.

4. (currently amended) The compound of claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are, independently, selected from the group consisting of hydrogen, methyl, ethyl, butyl, ~~phenyl~~, benzyl, 2-bromobenzyl, 2-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 2,4,6-trichlorobenzyl, 2-fluorobenzyl, 4-fluorobenzyl, 2,4-difluorobenzyl, 2,6-difluorobenzyl, 2,4,6-trifluorobenzyl, 2-chloro-4-fluorobenzyl, 2-fluoro-4-bromobenzyl, 2-fluoro-4-chlorobenzyl, 2-methylbenzyl, 2-methylsulfonylbenzyl, 2-trifluoromethylbenzyl, 1-phenyleth-1-yl, 1-phenylprop-1-yl, 1-(4-bromophenyl)eth-1-yl, 1-(4-fluorophenyl)eth-1-yl, 1-(2,4-dibromophenyl)eth-1-yl, 1-(2,4-dichlorophenyl)eth-1-yl, 1-(3,4-dichlorophenyl)eth-1-yl, 1-(2,4-difluorophenyl)eth-1-yl, 1-(4-methylphenyl)eth-1-yl, 1-methyl-1-phenyleth-1-yl, 1-phenyl-2-dimethylaminoeth-1-yl, 1-benzoyleth-1-yl, cyclohexyl, 1-cyclohexyleth-1-yl,

furan-2-ylmethyl, naphth-1-ylmethyl, methoxy, methylsethyl,  
6-methyl-6-hydroxyhept-2-yl, pyrid-2-ylethyl, 1,2,3,4-tetrahydro-naphthalen-1-yl,  
1-phenyl-2-hydroxyethyl-1-yl, benzhydryl, 4-hydroxymethylpiperidin-1-yl,  
1-furan-2-yl-2-phenyleth-1-yl and 9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl.

5. (original) The compound of claim 1 wherein one of  $R^1$  and  $R^2$  is H or  $C_{1-4}$ alkyl where the other is not H or  $C_{1-4}$ alkyl.
6. (original) The compound of claim 1 wherein one of  $R^1$  and  $R^2$  is H, methyl or ethyl.

7. (original) The compound of claim 1 wherein, at least one of  $R^1$  and  $R^2$  are, independently, selected from the groups consisting of



where  $R^s$  is not hydrogen, said phenyl is optionally fused at two adjacent carbon atoms to  $R^f$  and, except in positions where  $R^s$  is indicated, each member is substituted with 0, 1, 2, or 3 of  $R^q$ .

8. (original) The compound of claim 1 wherein  $R^f$  is selected from the group consisting of  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2CH_2-$  and  $-(C=O)CH_2CH_2CH_2-$ .
9. (original) The compound of claim 1 wherein  $R^s$  is selected from the group consisting of hydrogen, methyl, ethyl, propyl, trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl, thiomethyl, methylthiomethyl and phenyl.

10. (original) The compound of claim 1 wherein R<sup>s</sup> is selected from the group consisting of H, methyl, ethyl, hydroxymethyl and dimethylaminomethyl.
11. (original) The compound of claim 1 wherein R<sup>q</sup> is selected from the group consisting of methyl, ethyl, propyl, t-butyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl, thiomethyl, methylthiomethyl, methoxy, ethoxy, methylmercapto and ethylmercapto.
12. (original) The compound of claim 1 wherein R<sup>q</sup> is selected from the group consisting of methyl, hydroxy, fluoro, chloro, bromo, iodo and trifluoromethyl.
13. (original) The compound of claim 1 wherein, R<sup>1</sup> and R<sup>2</sup> taken together with the nitrogen to which they are attached are selected from the group consisting of
- i) 10-Oxa-4-aza-tricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl,
  - ii) 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, 3-(H or R<sup>p</sup>)imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 3-(H or R<sup>p</sup>)piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl, azetidin-1-yl, where each member of ii) in each ring has 0 or 1 unsaturated bond and has 0, 1 or 2 carbon members which is a carbonyl,
  - iii) 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl, 2,3-dihydro-indol-1-yl, 1,3-dihydro-isindol-2-yl, 1-oxo-1,3-dihydro-isindol-2-yl, tetrahydro-benzo[b, c or d]azepin-1-yl, where each member of iii) in each ring has 0 or 1 unsaturated bond and has 0, 1 or 2 carbon members which are a carbonyl,
  - iv) decahydro-quinolin-1-yl, octahydro-isoquinolin-2-yl, octahydro-[1 or 2]pyrindin-1 or 2-yl, octahydro-indol-1-yl, octahydro-isindol-2-yl, hexahydro-cyclopenta[b]pyrrol-1-yl, hexahydro-cyclopenta[c]pyrrol-2-yl, (5,6,7 or 8-H or R<sup>p</sup>)-decahydro-[1,5 or 1,6 or 1,7 or 1,8]naphthyridin-1-yl, (5,6,7 or 8-H or R<sup>p</sup>)-decahydro-[2,5 or 2,6 or 2,7 or 2,8]naphthyridin-2-yl, 1-H or R<sup>p</sup>-octahydro-pyrrolo[2,3-c]pyridin-6-yl, 2-H or R<sup>p</sup>-octahydro-pyrrolo[3,4-c]pyridin-5-yl, 1-H or R<sup>p</sup>-octahydro-pyrrolo[3,2-c]pyridin-5-yl, 1-H or R<sup>p</sup>-octahydro-pyrrolo[2,3-b]pyridin-7-yl, 6-H or R<sup>p</sup>-octahydro-

pyrrolo[3,4-b]pyridin-1-yl, 1-H or R<sup>p</sup>-octahydro-pyrrolo[3,2-b]pyridin-4-yl, 5-H or R<sup>p</sup>-octahydro-pyrrolo[3,4-c]pyridin-2-yl, 6-H or R<sup>p</sup>-octahydro-pyrrolo[2,3-c]pyridin-1-yl, 1-H or R<sup>p</sup>-octahydro-pyrrolo[3,4-b]pyridin-6-yl, 7-H or R<sup>p</sup>-octahydro-pyrrolo[2,3-b]pyridin-1-yl, octahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, where each member of iv) in each ring has 0, 1 or 2 carbon members which is a carbonyl, each ring of attachment has 0 or 1 unsaturated bonds and each secondary ring has 0, 1 or 2 unsaturated bonds,

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, where each member of i), ii), iii), iv) or v) is further substituted with 0, 1 or 2 of R<sup>p</sup>.

14. (original) The compound of claim 1 wherein, R<sup>1</sup> and R<sup>2</sup> taken together with the nitrogen to which they are attached are selected from the group consisting of 10-Oxa-4-aza-tricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl, 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl, 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, azetidin-1-yl, octahydro-quinolin-1-yl, 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl, where each member is further substituted with 0, 1 or 2 of R<sup>p</sup>.

15. (original) The compound of claim 1 wherein R<sup>1</sup> and R<sup>2</sup> taken together with the nitrogen to which they are attached are selected from the group consisting of 1-methyl-10-Oxa-4-aza-tricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl, azetidin-1-yl, pyrrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl, 2,4-dimethyl-3-ethylpyrrolidin-1-yl, piperidin-1-yl, 2-methylpiperidin-1-yl, 4-hydroxymethylpiperidin-1-yl, 4-phenylpiperidin-1-yl, azepan-1-yl, 4-(2-hydroxyphenyl)piperazin-1-yl, morpholin-4-yl, octahydro-isoquinolin-2-yl, decahydro-quinolin-1-yl, thiazolidin-3-yl, 2,5-dimethyl-2,5-dihydro-pyrrol-1-yl, 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl and 3,4-dihydro-2H-quinolin-2-yl.



16. (original) The compound of claim 1 wherein R<sup>p</sup> is selected from the group consisting of hydroxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, phenyl, p-halophenyl, m-halophenyl, o-halophenyl, phenyl and p-hydroxyphenyl.
17. (original) The compound of claim 1 wherein R<sup>p</sup> is selected from the group consisting of hydroxy, methyl, ethyl, hydroxymethyl, hydroxyethyl, phenyl, mono-fluorosubstituted phenyl and mono-chlorosubstituted phenyl.
18. (original) The compound of claim 1 wherein R<sup>a</sup> is selected from the group consisting of methyl, ethyl, propyl, ethenyl, propenyl, cyclopropyl, cyclobutyl, phenyl, furanyl, thienyl, pyrrol-1-yl, benzyl, methoxy, ethoxy, propoxy, cyclopropoxy, cyclobutoxy, cyclopentoxo, phenoxy, benzoxy, -SH, -Smethyl, -Sethyl, -S-t-butyl, -Scyclopropyl, -Sphenyl, -Sbenzyl, nitro, cyano, amino, dimethylamino, (cyclohexylmethyl)amino, acetyl, -SCF<sub>3</sub>, I, F, Cl, Br, trifluoromethyl, -OCF<sub>3</sub> and carboxymethyl.
19. (original) The compound of claim 1 wherein there is one R<sup>a</sup>.
20. (original) The compound of claim 1 wherein there is one R<sup>a</sup> positioned on the ring para to the amide substituent.
21. (original) The compound of claim 1 wherein two adjacent R<sup>a</sup> are taken together with the carbons of attachment to form a fused ring.
22. (original) The compound of claim 21 wherein the fused ring is benzo.
23. (original) The compound of claim 1 wherein R<sup>a</sup> is selected from the group consisting of nitro, F, Cl, Br, fused benzo, I, CF<sub>3</sub>, methoxy, ethoxy, propoxy, i-propoxy, ethenyl, cyclopentoxo, 2-propenyl, phenyl, furanyl, thienyl, amino, pyrrol-1-yl, dimethylamino, (cyclohexylmethyl)amino, -SCH<sub>3</sub>, -Sethyl, -S-t-butyl, -Sbenzyl, -SCF<sub>3</sub>, i-propyl and methyl.

24. (original) The compound of claim 1 wherein R<sup>b</sup> is absent or selected from the group consisting of methyl, ethyl, I, F, Cl and Br.

25. (original) The compound of claim 1 wherein R<sup>b</sup> is absent.

26. (original) The compound of claim 1 wherein said pharmaceutically acceptable salts are selected from the group consisting of hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, malate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate and laurylsulfonate salts.

27. (canceled) A compound selected from the group consisting of:

EX	Compound
1	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide
2	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-amide
3	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide
4	Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-(piperidine-1-carbonyl)-naphthalen-2-yl]-amide
5	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide
6	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide
10	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methoxy-2-(piperidine-1-carbonyl)-phenyl]-amide
11	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethoxy-2-(piperidine-1-carbonyl)-phenyl]-amide
12	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propoxy-

	phenyl]-amide
13	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropoxy-2-(piperidine-1-carbonyl)-phenyl]-amide
14	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-cyclopentyloxy-2-(piperidine-1-carbonyl)-phenyl]-amide
15	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-vinyl-phenyl]-amide
16	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-allyl-2-(piperidine-1-carbonyl)-phenyl]-amide
17	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethyl-2-(piperidine-1-carbonyl)-phenyl]-amide
18	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propyl-phenyl]-amide
19	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(piperidine-1-carbonyl)-biphenyl-3-yl]-amide
20	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-2-yl-2-(piperidine-1-carbonyl)-phenyl]-amide
21	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-3-yl-2-(piperidine-1-carbonyl)-phenyl]-amide
22	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-2-yl-phenyl]-amide
23	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-3-yl-phenyl]-amide
24	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide
25	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-pyrrol-1-yl-phenyl]-amide
26	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-dimethylamino-2-(piperidine-1-carbonyl)-phenyl]-amide
27	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-(cyclohexylmethyl-amino)-2-

	(piperidine-1-carbonyl)-phenyl]-amide
28	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide
29	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide
30	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isobutylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide
31	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-benzylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide
32	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide
33	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-fluoro-2-(piperidine-1-carbonyl)-phenyl]-amide
34	Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide
35	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dibromo-2-(piperidine-1-carbonyl)-phenyl]-amide
36	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dichloro-2-(piperidine-1-carbonyl)-phenyl]-amide
37	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropyl-2-(piperidine-1-carbonyl)-phenyl]-amide
44	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(piperidine-1-carbonyl)-phenyl]-amide
54	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1-methyl-10-oxa-4-azatricyclo[5.2.1.0 <sup>2,6</sup> ]decane-4-carbonyl)-phenyl]-amide
60	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(pyrrolidine-1-carbonyl)-phenyl]-amide
62	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-hydroxymethyl-piperidine-1-carbonyl)-phenyl]-amide
63	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-[4-(2-hydroxy-phenyl)-

	piperazine-1-carbonyl]-phenyl]-amide
64	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-phenyl]-amide
66	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-2,5-dihydro-pyrrole-1-carbonyl)-phenyl]-amide
68	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azepane-1-carbonyl)-5-chloro-phenyl]-amide
70	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-methyl-piperidine-1-carbonyl)-phenyl]-amide
71	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-isoquinoline-2-carbonyl)-phenyl]-amide
72	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(3-ethyl-2,4-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide
73	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-phenyl-piperidine-1-carbonyl)-phenyl]-amide
75	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-quinoline-1-carbonyl)-phenyl]-amide
78	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azetidine-1-carbonyl)-5-chloro-phenyl]-amide
79	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(thiazolidine-3-carbonyl)-phenyl]-amide
80	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,2,3,4-tetrahydronaphthalene-2-carbonyl)-phenyl]-amide
89	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-carbonyl)-phenyl]-amide
90	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide
91	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(morpholine-4-carbonyl)-phenyl]-amide
137	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(morpholine-4-carbonyl)-

	phenyl]-amide
138	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide
139	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(morpholine-4-carbonyl)-phenyl]-amide
140	7-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide
177	5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide
178	7-Bromo-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide
182	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,3,4,5-tetrahydrobenzo[c]azepine-2-carbonyl)-phenyl]-amide

28. (canceled) A compound selected from the group consisting of:

EX	Compound
7	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-methylbenzamide
8	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-bromo-N-methylbenzamide
9	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-iodo-N-methylbenzamide
38	3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid (4-fluoro-benzyl)-methanamide
39	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-trifluoromethylbenzamide
40	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-fluorobenzamide
41	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-

	ethyl]-benzamide
42	( <i>R</i> )-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichlorophenyl)-ethyl]-4-methylbenzamide
43	( <i>R</i> )-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-dichlorophenyl)-ethyl]-benzamide
45	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-benzyl)-benzamide
46	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-(5-hydroxy-1,5-dimethylhexyl)benzamide
47	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methylsulfonyl-benzyl)benzamide
48	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-dimethylamino-1-phenyl-ethyl)-N-methylbenzamide TFA salt
49	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-ethyl-benzamide
50	N-Benzhydryl-2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-benzamide
51	( <i>S</i> ) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide
52	( <i>R</i> ) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide
53	( <i>R</i> ) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-ethyl)-benzamide
55	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-2-fluoro-benzyl)-4-chloro-benzamide
56	( <i>R</i> ) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-bromo-phenyl)-ethyl]-4-chloro-benzamide
57	( <i>R</i> ) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-p-tolyl-ethyl)-benzamide
58	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-phenyl-

	benzamide
59	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-butyl-4-chloro-benzamide
61	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide
65	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N,N-diethyl-benzamide
67	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-furan-2-ylmethyl-N-methyl-benzamide
69	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-naphthalen-1-ylmethyl-benzamide
74	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-cyclohexyl-N-methyl-benzamide
76	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-cyclohexylethyl)-benzamide
77	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-benzamide
81	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-benzamide
82	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-fluoro-benzyl)-benzamide
83	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-benzamide
84	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(3,4-dichloro-benzyl)-benzamide
85	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-benzamide
86	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-benzamide
87	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-benzamide
88	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4-dichloro-



	phenyl)-ethyl]-benzamide
92	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-2-fluoro-benzyl)-benzamide
93	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-benzamide
94	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-trifluoromethyl-benzyl)-benzamide
95	(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-phenyl-ethyl)-benzamide
96	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-benzyl)-4-chloro-benzamide
97	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-propyl)-benzamide
98	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methyl-benzyl)-benzamide
99	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-bromo-benzyl)-4-chloro-benzamide
100	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-methyl-N-(1-phenyl-ethyl)-benzamide
101	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-(1-phenyl-ethyl)-benzamide
102	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-benzamide
103	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-N-methyl-benzamide
104	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-N-methyl-benzamide
105	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4-iodo-N-methyl-benzamide
106	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-

	iodo-N-methyl-benzamide
107	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide
108	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide
109	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide
110	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide
111	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-N-methyl-benzamide
112	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide
113	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-N-methyl-benzamide
114	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-benzamide
115	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(1-phenyl-ethyl)-benzamide
116	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-phenyl-ethyl)-benzamide
117	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methoxy-N-methyl-benzamide
118	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide
119	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-benzamide
120	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-methyl-benzamide
121	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-

	benzamide
122	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-N-methyl-benzamide
123	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4,N-dimethyl-benzamide
124	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide
125	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide
126	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide
127	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4,N-dimethyl-benzamide
128	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide
129	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide
130	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide
131	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-benzamide
132	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-benzamide
133	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-methyl-benzamide
134	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-benzamide
135	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-benzamide
136	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4,N-dimethyl-benzamide


141	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-difluoro-benzyl)-benzamide
142	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-dichloro-benzyl)-benzamide
143	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trifluoro-benzyl)-benzamide
144	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trichloro-benzyl)-benzamide
145	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-methyl-1-phenyl-ethyl)-benzamide
146	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide
147	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide
148	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-difluoro-benzyl)-benzamide
149	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-dichloro-benzyl)-benzamide
150	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trifluoro-benzyl)-benzamide
151	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trichloro-benzyl)-benzamide
152	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-benzamide
153	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-methyl-1-phenyl-ethyl)-benzamide
154	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide
155	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide

156	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trifluoro-benzyl)-benzamide
157	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trichloro-benzyl)-benzamide
158	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-benzamide
159	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-iodo-benzamide
160	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-iodo-benzamide
161	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-benzamide
162	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4,6-trifluoro-benzyl)-benzamide
163	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-benzamide
164	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trifluoro-benzyl)-benzamide
165	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trichloro-benzyl)-benzamide
166	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-methyl-benzamide
167	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-methyl-benzamide
168	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-benzamide
169	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide
170	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,N-dimethyl-N-(1-phenyl-ethyl)-benzamide

171	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-N-methyl-benzamide
172	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4,N-dimethyl-benzamide
173	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide
174	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4,N-dimethyl-benzamide
175	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-benzamide
176	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-5-chloro-N-methyl-benzamide
179	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methylsulfonyl-benzyl)-benzamide
180	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-N-methyl-benzamide
181	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-N-methyl-benzamide
183	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide
184	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-fluoro-benzyl)-N-methyl-benzamide
185	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-chloro-benzyl)-N-methyl-benzamide
186	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-4-iodo-benzamide
187	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-chloro-phenyl)-ethyl]-4-iodo-benzamide
188	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-4-iodo-N-methyl-benzamide

189	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-4-iodo-N-methyl-benzamide
190	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-trifluoromethyl-benzamide
191	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-4-trifluoromethyl-benzamide
192	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-N-methyl-4-trifluoromethyl-benzamide
193	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-N-methyl-4-trifluoromethyl-benzamide
194	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-4-trifluoromethyl-benzamide
195	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-methyl-N-(1-phenyl-ethyl)-4-trifluoromethyl-benzamide
196	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-fluoro-benzamide
197	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-fluoro-N-methyl-benzamide
198	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluoro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide

29. (currently amended) A pharmaceutical composition comprising a suitable amount of inert pharmaceutically acceptable diluent and a pharmaceutically efficacious amount of a compound of formula (I):



wherein

R<sup>1</sup> and R<sup>2</sup> are each independently selected from the group consisting of

- a) H, C<sub>1-7</sub>alkyl, C<sub>2-7</sub>alkenyl, C<sub>2-7</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkenyl, benzo-fused C<sub>4-7</sub>cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C<sub>3-7</sub>cycloalkyl C<sub>1-7</sub>alkyl,
  - b) naphthyl-(CR<sup>s</sup>)<sub>2</sub>-, benzoyl C<sub>0-3</sub>alkyl-(CR<sup>s</sup>)<sub>2</sub>-, ~~phenyl-, said phenyl optionally~~ fused at two adjacent carbon atoms to R<sup>f</sup>, phenyl-(CR<sup>s</sup>)<sub>2</sub>-, said phenyl optionally fused at two adjacent carbon atoms to R<sup>f</sup>,
- R<sup>f</sup> is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,
- c) Ar<sup>6</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6</sup> is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused,
  - d) Ar<sup>5</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>5</sup> is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzofused,
  - e) Ar<sup>6-6</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6-6</sup> is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,
  - f) Ar<sup>6-5</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6-5</sup> is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl and having 0 or 1 additional heteroatom member which is -N=,
  - g) C<sub>1-4</sub>alkylO- and HSC<sub>1-4</sub>alkyl,



where  $R^1$  and  $R^2$  are not simultaneously H and, except in positions where  $R^s$  is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of  $R^q$ ,  
 $R^q$  is independently selected from the group consisting of  $C_{1-4}$ alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, amino $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, di $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, HO- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylO- $C_{1-4}$ alkyl, HS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy and  $C_{1-4}$ alkylS-,  
 $R^s$  is independently selected from the group consisting of hydrogen,  $C_{1-4}$ alkyl, trifluoromethyl, amino $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, di $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, HO- $C_{1-4}$ alkyl, HS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylS- $C_{1-4}$ alkyl and phenyl;

or, alternatively,

$R^1$  and  $R^2$  may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl, optionally mono- or di-substituted with  $R^p$ ,

$R^p$  is independently selected from the group consisting of hydroxy,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents  $R^p$ ,


iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents  $R^p$ ,

- iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R<sup>P</sup>;
- v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R<sup>P</sup>;

R<sup>a</sup> is, independently, selected from the group consisting of -C<sub>1-6</sub>alkyl, -C<sub>2-6</sub>alkenyl, -C<sub>3-6</sub>cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC<sub>1-6</sub>alkyl, -OC<sub>3-6</sub>cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC<sub>1-6</sub>alkyl, -SC<sub>3-6</sub>cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO<sub>2</sub>, -N(R<sup>y</sup>)R<sup>z</sup> (wherein R<sup>y</sup> and R<sup>z</sup> are independently selected from H, C<sub>1-4</sub>alkyl or C<sub>1-6</sub>cycloalkylC<sub>1-4</sub>alkyl), -(C=O)C<sub>1-4</sub>alkyl, -SCF<sub>3</sub>, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, and -COOC<sub>1-4</sub>alkyl, or, alternatively, two adjacent R<sup>a</sup>, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R<sup>b</sup> is, independently, selected from the group consisting of -C<sub>1-4</sub>alkyl and halogen; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

30. (canceled) A method for treating or preventing CCK2 mediated disease states comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):



wherein

R<sup>1</sup> and R<sup>2</sup> are each independently selected from the group consisting of

- a) H, C<sub>1-7</sub>alkyl, C<sub>2-7</sub>alkenyl, C<sub>2-7</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkenyl, benzo-fused C<sub>4-7</sub>cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C<sub>3-7</sub>cycloalkylC<sub>1-7</sub>alkyl,
- b) naphthyl-(CR<sup>s</sup>)<sub>2</sub>-, benzoylC<sub>0-3</sub>alkyl-(CR<sup>s</sup>)<sub>2</sub>-, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R<sup>f</sup>, phenyl-(CR<sup>s</sup>)<sub>2</sub>-, said phenyl optionally fused at two adjacent carbon atoms to R<sup>f</sup>,

R<sup>f</sup> is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

- c) Ar<sup>6</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6</sup> is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused,
- d) Ar<sup>5</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>5</sup> is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzofused,
- e) Ar<sup>6-6</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6-6</sup> is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,
- f) Ar<sup>6-5</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6-5</sup> is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl and having 0 or 1 additional heteroatom member which is -N=,
- g) C<sub>1-4</sub>alkylO- and HSC<sub>1-4</sub>alkyl,

where  $R^1$  and  $R^2$  are not simultaneously H and, except in positions where  $R^s$  is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of  $R^q$ ,  
 $R^q$  is independently selected from the group consisting of  $C_{1-4}$ alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, amino $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, di $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, HO- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylO- $C_{1-4}$ alkyl, HS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy and  $C_{1-4}$ alkylS-,  
 $R^s$  is independently selected from the group consisting of hydrogen,  $C_{1-4}$ alkyl, trifluoromethyl, amino $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, di $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, HO- $C_{1-4}$ alkyl, HS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylS- $C_{1-4}$ alkyl and phenyl;

or, alternatively,

$R^1$  and  $R^2$  may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl, optionally mono- or di-substituted with  $R^p$ ,

$R^p$  is independently selected from the group consisting of hydroxy,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents  $R^p$ ,


iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents  $R^p$ ,

- iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R<sup>P</sup>;
- v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R<sup>P</sup>;

R<sup>a</sup> is, independently, selected from the group consisting of -C<sub>1-6</sub>alkyl, -C<sub>2-6</sub>alkenyl, -C<sub>3-6</sub>cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC<sub>1-6</sub>alkyl, -OC<sub>3-6</sub>cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC<sub>1-6</sub>alkyl, -SC<sub>3-6</sub>cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO<sub>2</sub>, -N(R<sup>y</sup>)R<sup>z</sup> (wherein R<sup>y</sup> and R<sup>z</sup> are independently selected from H, C<sub>1-4</sub>alkyl or C<sub>1-6</sub>cycloalkylC<sub>1-4</sub>alkyl), -(C=O)C<sub>1-4</sub>alkyl, -SCF<sub>3</sub>, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, and -COOC<sub>1-4</sub>alkyl, or, alternatively, two adjacent R<sup>a</sup>, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R<sup>b</sup> is, independently, selected from the group consisting of -C<sub>1-4</sub>alkyl and halogen; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

31. (canceled) A method for treating or preventing pancreatic adenocarcinoma, pain, eating disorders, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors, gastric tumors, Barrett's esophagus, antral G cell hyperplasia, pernicious anaemia and Zollinger-Ellison syndrome comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):



wherein

$R^1$  and  $R^2$  are each independently selected from the group consisting of

- a) H,  $C_{1-7}$ alkyl,  $C_{2-7}$ alkenyl,  $C_{2-7}$ alkynyl,  $C_{3-7}$ cycloalkyl,  $C_{3-7}$ cycloalkenyl, benzo-fused  $C_{4-7}$ cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction,  $C_{3-7}$ cycloalkyl  $C_{1-7}$ alkyl,
- b) naphthyl- $(CR^s_2)$ -, benzoyl  $C_{0-3}$ alkyl- $(CR^s_2)$ -, phenyl, said phenyl optionally fused at two adjacent carbon atoms to  $R^f$ , phenyl- $(CR^s_2)$ -, said phenyl optionally fused at two adjacent carbon atoms to  $R^f$ ,  
 $R^f$  is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,
- c)  $Ar^6-(CR^s_2)$ -, where  $Ar^6$  is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused,
- d)  $Ar^5-(CR^s_2)$ -, where  $Ar^5$  is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzofused,
- e)  $Ar^{6-6}-(CR^s_2)$ -, where  $Ar^{6-6}$  is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,
- f)  $Ar^{6-5}-(CR^s_2)$ -, where  $Ar^{6-5}$  is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl and having 0 or 1 additional heteroatom member which is -N=,
- g)  $C_{1-4}$ alkylO- and HSC<sub>1-4</sub>alkyl,

where  $R^1$  and  $R^2$  are not simultaneously H and, except in positions where  $R^s$  is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of  $R^q$ ,  
 $R^q$  is independently selected from the group consisting of  $C_{1-4}$ alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, amino $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, di $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, HO- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylO- $C_{1-4}$ alkyl, HS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy and  $C_{1-4}$ alkylS-,  
 $R^s$  is independently selected from the group consisting of hydrogen,  $C_{1-4}$ alkyl, trifluoromethyl, amino $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, di $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, HO- $C_{1-4}$ alkyl, HS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylS- $C_{1-4}$ alkyl and phenyl;  
or, alternatively,

$R^1$  and  $R^2$  may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl, optionally mono- or di-substituted with  $R^p$ ,

$R^p$  is independently selected from the group consisting of hydroxy,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents  $R^p$ ,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents  $R^p$ ,


- iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R<sup>P</sup>;
- v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R<sup>P</sup>;

R<sup>a</sup> is, independently, selected from the group consisting of -C<sub>1-6</sub>alkyl, -C<sub>2-6</sub>alkenyl, -C<sub>3-6</sub>cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC<sub>1-6</sub>alkyl, -OC<sub>3-6</sub>cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC<sub>1-6</sub>alkyl, -SC<sub>3-6</sub>cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO<sub>2</sub>, -N(R<sup>y</sup>)R<sup>z</sup> (wherein R<sup>y</sup> and R<sup>z</sup> are independently selected from H, C<sub>1-4</sub>alkyl or C<sub>1-6</sub>cycloalkylC<sub>1-4</sub>alkyl), -(C=O)C<sub>1-4</sub>alkyl, -SCF<sub>3</sub>, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, and -COOC<sub>1-4</sub>alkyl, or, alternatively, two adjacent R<sup>a</sup>, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R<sup>b</sup> is, independently, selected from the group consisting of -C<sub>1-4</sub>alkyl and halogen; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

32. (canceled) A method for treating or preventing pancreatic adenocarcinoma, pain, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors and gastric tumors comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):





wherein

R<sup>1</sup> and R<sup>2</sup> are each independently selected from the group consisting of

- a) H, C<sub>1-7</sub>alkyl, C<sub>2-7</sub>alkenyl, C<sub>2-7</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkenyl, benzo-fused C<sub>4-7</sub>cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C<sub>3-7</sub>cycloalkylC<sub>1-7</sub>alkyl,
- b) naphthyl-(CR<sup>s</sup>)<sub>2</sub>-, benzoylC<sub>0-3</sub>alkyl-(CR<sup>s</sup>)<sub>2</sub>-, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R<sup>f</sup>, phenyl-(CR<sup>s</sup>)<sub>2</sub>-, said phenyl optionally fused at two adjacent carbon atoms to R<sup>f</sup>,

R<sup>f</sup> is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

- c) Ar<sup>6</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6</sup> is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused,
- d) Ar<sup>5</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>5</sup> is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzofused,
- e) Ar<sup>6-6</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6-6</sup> is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,
- f) Ar<sup>6-5</sup>-(CR<sup>s</sup>)<sub>2</sub>-, where Ar<sup>6-5</sup> is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC<sub>1-4</sub>alkyl and having 0 or 1 additional heteroatom member which is -N=,
- g) C<sub>1-4</sub>alkylO- and HSC<sub>1-4</sub>alkyl,

where  $R^1$  and  $R^2$  are not simultaneously H and, except in positions where  $R^s$  is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of  $R^q$ ,  
 $R^q$  is independently selected from the group consisting of  $C_{1-4}$ alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, amino $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, di $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, HO- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylO- $C_{1-4}$ alkyl, HS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy and  $C_{1-4}$ alkylS-,  
 $R^s$  is independently selected from the group consisting of hydrogen,  $C_{1-4}$ alkyl, trifluoromethyl, amino $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, di $C_{1-4}$ alkylamino $C_{1-4}$ alkyl, HO- $C_{1-4}$ alkyl, HS- $C_{1-4}$ alkyl,  $C_{1-4}$ alkylS- $C_{1-4}$ alkyl and phenyl;

or, alternatively,

$R^1$  and  $R^2$  may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl, optionally mono- or di-substituted with  $R^p$ ,

$R^p$  is independently selected from the group consisting of hydroxy,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents  $R^p$ ,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>p</sup>, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents  $R^p$ ,

- iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR<sup>P</sup>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R<sup>P</sup>;
- v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R<sup>P</sup>;

R<sup>a</sup> is, independently, selected from the group consisting of -C<sub>1-6</sub>alkyl, -C<sub>2-6</sub>alkenyl, -C<sub>3-6</sub>cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC<sub>1-6</sub>alkyl, -OC<sub>3-6</sub>cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC<sub>1-6</sub>alkyl, -SC<sub>3-6</sub>cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO<sub>2</sub>, -N(R<sup>y</sup>)R<sup>z</sup> (wherein R<sup>y</sup> and R<sup>z</sup> are independently selected from H, C<sub>1-4</sub>alkyl or C<sub>1-6</sub>cycloalkylC<sub>1-4</sub>alkyl), -(C=O)C<sub>1-4</sub>alkyl, -SCF<sub>3</sub>, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, and -COOC<sub>1-4</sub>alkyl, or, alternatively, two adjacent R<sup>a</sup>, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R<sup>b</sup> is, independently, selected from the group consisting of -C<sub>1-4</sub>alkyl and halogen; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

33. (new) A compound selected from the group consisting of:

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-(piperidine-1-carbonyl)-naphthalen-2-yl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methoxy-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethoxy-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propoxy-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropoxy-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-cyclopentyloxy-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-vinyl-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-allyl-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethyl-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propyl-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(piperidine-1-carbonyl)-biphenyl-3-yl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-2-yl-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-3-yl-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-2-yl-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-3-yl-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-pyrrol-1-yl-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-dimethylamino-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-(cyclohexylmethyl-amino)-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isobutylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-benzylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-fluoro-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dibromo-2-(piperidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dichloro-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropyl-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1-methyl-10-oxa-4-azatricyclo[5.2.2.1.0<sup>2,6</sup>]decane-4-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(pyrrolidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-hydroxymethyl-piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid {5-chloro-2-[4-(2-hydroxy-phenyl)-piperazine-1-carbonyl]-phenyl}-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-2,5-dihydro-pyrrole-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azepane-1-carbonyl)-5-chloro-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-methyl-piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-isoquinoline-2-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(3-ethyl-2,4-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-phenyl-piperidine-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-quinoline-1-carbonyl)-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azetidine-1-carbonyl)-5-chloro-phenyl]-amide,

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(thiazolidine-3-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(morpholine-4-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(morpholine-4-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide,  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(morpholine-4-carbonyl)-phenyl]-amide,  
7-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide,  
5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide,  
7-Bromo-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide and  
Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide.

34. (new) A compound selected from the group consisting of:

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-bromo-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-iodo-N-methyl-benzamide,  
3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid (4-fluoro-benzyl)-methylethylamide,

(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-trifluoromethylbenzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-fluorobenzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichlorophenyl)-ethyl]-4-methylbenzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-(5-hydroxy-1,5-dimethylhexyl)benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methylsulfonyl-benzyl)benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-dimethylamino-1-phenyl-ethyl)-N-methylbenzamide TFA salt,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-ethyl-benzamide,  
N-Benzhydryl-2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-benzamide,  
(*S*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide,  
(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide,  
(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-ethyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-2-fluoro-benzyl)-4-chloro-benzamide,  
(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-bromo-phenyl)-ethyl]-4-chloro-benzamide,



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-*p*-tolyl-ethyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-butyl-4-chloro-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N,N-diethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-furan-2-ylmethyl-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-naphthalen-1-ylmethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-cyclohexyl-N-methyl-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-cyclohexyl-ethyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-fluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(3,4-dichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4-dichloro-phenyl)-ethyl]-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-2-fluoro-benzyl)-benzamide,

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-trifluoromethyl-benzyl)-benzamide,  
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-phenylethyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-benzyl)-4-chloro-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-propyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methyl-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-bromo-benzyl)-4-chloro-benzamide,  
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-methyl-N-(1-phenyl-ethyl)-benzamide,  
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-(1-phenyl-ethyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-N-methylbenzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-N-methylbenzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4-iodo-N-methylbenzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-N-methylbenzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-N-methylbenzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methylbenzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-N-methylbenzamide,

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(1-phenyl-ethyl)-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-phenyl-ethyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methoxy-N-methyl-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4,N-dimethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide,

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4,N-dimethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4,N-dimethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-difluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-dichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trifluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-methyl-1-phenyl-ethyl)-benzamide,  
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide,  
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide,

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-difluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-dichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trifluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-methyl-1-phenyl-ethyl)-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trifluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-iodo-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-iodo-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4,6-trifluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trifluoro-benzyl)-benzamide,

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trichloro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-methyl-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,N-dimethyl-N-(1-phenyl-ethyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4,N-dimethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4,N-dimethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-5-chloro-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methylsulfanyl-benzyl)-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide,

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-fluoro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-chloro-benzyl)-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-4-iodo-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-chloro-phenyl)-ethyl]-4-iodo-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-4-iodo-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-4-iodo-N-methyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-trifluoromethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-4-trifluoromethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-N-methyl-4-trifluoromethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-N-methyl-4-trifluoromethyl-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-4-trifluoromethyl-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-methyl-N-(1-phenyl-ethyl)-4-trifluoromethyl-benzamide,  
(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-fluoro-benzamide,  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-fluoro-N-methyl-benzamide  
and  
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluoro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide.